RecruitingNCT02917707
Integrative Analysis of CRC Liver Metastasis
Sponsor
Da Fu
Enrollment
1,000 participants
Start Date
Jan 1, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
The investigators will perform integrative analysis of CRC liver metastasis
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Plain Language Summary
Simplified for easier understanding
This study collects tissue samples and health information from patients with colorectal cancer (bowel cancer) that has spread to the liver, to better understand the biology of these liver metastases and find new targets for treatment.
**You may be eligible if...**
- You are 75 years old or younger
- You have been diagnosed with colorectal cancer (confirmed by biopsy)
- You are in good physical health (able to perform daily activities)
- You have not previously received chemotherapy for this cancer
**You may NOT be eligible if...**
- You are 76 years old or older
- You have already had chemotherapy for this cancer
- You have serious heart, liver, kidney, or other organ problems
- You are in poor overall health
Understanding the biology of bowel cancer that has spread to the liver is key to developing better treatments for this challenging condition. Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERnormal colorectal tissues
The investigators will extract total protein, DNA and RNA from these groups.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02917707
Related Trials
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT0686327275 locations
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT050952073 locations
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT063623695 locations
Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study
NCT067870141 location
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
NCT074774577 locations